公司資料
NextCure 股價、新聞與催化劑
- 股票代碼:
- NXTC
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
7.71 USD (-6.09%)
收盤價
最後更新: 2026年8月17日
12.3M USD
市值
股價為何變動
As of Aug 17, 2026, NXTC closed down 6.09% at $7.71. No new same-company headline was identified in the current news window.
公司概覽
Oncology Drug Development
NextCure develops novel therapies for cancer, with a pipeline that includes antibody-drug conjugates and immune-modulating approaches.
SIM0505
SIM0505 is an antibody-drug conjugate targeting cadherin-6 and carrying a topoisomerase-1 inhibitor payload. It is being evaluated in tumors with elevated CDH6 expression, including platinum-resistant ovarian cancer.
LNCB74
LNCB74 is a separate Phase 1 oncology candidate undergoing dose escalation, providing NextCure with a second clinical-stage program.
未來催化劑
- Phase 1 dose-escalation data for SIM0505 at ASCO 2026.
- Phase 1 dose-escalation update for LNCB74 in the second half of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。